APA (7th ed.) Citation

Matulonis, U. A., Vergote, I., Moore, K. N., Martin, L. P., Castro, C. M., Gilbert, L., . . . O'Malley, D. M. (2025). Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer. Gynecologic Oncology, 200, 96. https://doi.org/10.1016/j.ygyno.2025.06.016

Chicago Style (17th ed.) Citation

Matulonis, Ursula A., et al. "Safety and Efficacy of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)–targeting Antibody-drug Conjugate (ADC), in Combination with Pembrolizumab in Patients with Platinum-resistant Ovarian Cancer." Gynecologic Oncology 200 (2025): 96. https://doi.org/10.1016/j.ygyno.2025.06.016.

MLA (9th ed.) Citation

Matulonis, Ursula A., et al. "Safety and Efficacy of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)–targeting Antibody-drug Conjugate (ADC), in Combination with Pembrolizumab in Patients with Platinum-resistant Ovarian Cancer." Gynecologic Oncology, vol. 200, 2025, p. 96, https://doi.org/10.1016/j.ygyno.2025.06.016.